Power Law company profile

MYR

Biotech & Life Sciences · Bad Homburg, Germany · Founded 2011 Unicorn

Biotech company developing and commercialising novel therapies for chronic hepatitis D

Valuation

$1–2.5B

Latest valuation · 2026

Unlock exact value

Headcount

<100

Current team size

Unlock exact value

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

4 investors on MYR's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage

HTGF

Series A 1 investor entered at this stage

Joint Journey

Series B+ 2 investors entered at this stage

INSERM

University of Heidelberg

Global footprint

Where MYR has talent and traffic

Workforce by country

🇩🇪 Germany · Bad Homburg HQ

Book a demo for the full country breakdown

Web traffic by country

300 monthly visits
across markets

🇨🇦 Canada100%

Top 1 markets shown

Patent intelligence

$4M patent portfolio · 2 active families

Estimated portfolio value

$4M

0.28% of valuation · 1990.4× smaller than top peer Janssen Vaccines ($7.1B)

2 active patent families

Where MYR innovates Combination therapyHepatitis DAdefovirActive ingredientChronic hepatitis

Where MYR concentrates vs peers

Each axis is a top-10 topic across MYR and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about MYR

An AI-synthesized read of the highest-engagement posts about MYR on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See MYR on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles